olet spectrophotometric analysis of barbiturates. Am J Clin Pathol 
reliable analytically and equally informative clinically. Because of its rapid implementation, the anti-TPO assay may advantageously replace anti-Mic Ab assay, especially for forming a prognosis of Graves disease.
AddItIonalK.yphrasu: radloimmunoassay immunoradlomettic assay autoantibodies effect of carbimazole treatment
Graves disease (GD)is an autoimmune disease in which antibodies (Ab) are active against thyroid mlcrosomal antigens (1). Unfortunately, the methods currently used to measure anti-microsomal (anti-Mic) Ab concentration rely on thyroid membrane preparations contaminated with other antigens, especially thyroglobulin, which is also involved in thyroid autoimmunity. Thyroid peroxidase (TPO) has recently been identified as a thyroid microsomal antigen (2, 3) . Taking advantage of highly purified TPO and of a carefully selected monoclonal anti-TPO Ab, Ruf et al. ( analytically, by qualitative assessment of the two methods, and clinically, by correlating the results observed in GDpatients before and after drug therapy. We also determined the utility of anti-Mic or anti-TPO Ab concentrations as prognostic markers of GD.
MaterIals and Methods

Patients
The study involved 52 GD patients diagnosed from typical clinical signs: goiter, occasional exophthalmos, and increased free thyroid hormone concentrations (free triiodothyronine >8.9 pmol/L and free thyroxin >23.4 pmol/L). Patients showing toxic nodules on computed tomographic scan were excluded. All patients were treated for six or 18 months with carbimazole (1-methyl-2-thio-3-carbethoxyimidazole),
initially at a high dose (40 mg/day), then with decreasing doses that maintained a euthyroid state without hormone replacement.
Twenty sex-and age-matehed healthy blood donors served as controls. Blood samples, taken before drug therapy and at the end of treatment, were collected in anticoagulant-free tubes and centrifuged at 1000 x g for lominat4#{176}C.Seraweredecantedforstorageat -20#{176}C until assay. scribed by the manufacturer 20 uL of serum was diluted with 750 L of buffer in tubes coated with microsomal antigens. After incubation for 2 h at 37#{176}C, the supernates were aspirated, the coated tubes were washed, and 1 mL of 'I-labeled ProteinA was added to each tube. After another 2-h incubation at 37#{176}C, the supernates were discarded and the tubes washed. The bound radioactivity in each tube was counted for 2 nun 
Antibody Assays
Analytical Vanables
The repeatability of anti-Mic and anti-TPO Ab assays was evaluated in terms of the within-run CV for 12 or 10 assays of three patients' sera.
The reproducibility was determined for 20 or 12 series of assays. Between-run CVs were computed from assays of two samples (one patient's serum and one commercial control sample). The between-run data were generated with 20 or six batches of kits for anti-Mic and anti-TPO Ab assays, respectively.
Statistics.
Quantitative analysis was performed with the Mann-Whitney U test and qualitative analysis with the x2 test.
Results
Analytical Variables
The repeatability and reproducibility of anti-Mic and anti-TPO Ab assays are reported in Table 1 . Betweenrun and within-run precision was satisfactory for both assays, with CVs <15%.
We serially diluted with antibody-free serum patients' sera rich in anti-Mic and anti-TPO Ab. The dilution curves ( Figure 1 )were parallel to the standard curves for each antibody. Twenty-nine of the 52 patients (Group I) were still in remission two years after drug withdrawal, whereas 23 had relapsed (Group II). Nineteen of the 29 Group I patients (65%) were anti-Mic Ab-positive (median 6035 units/mL, range 117-35 266), and 18 of these (62%) were anti-TPO Ab-positive (median 1435 units/mL, There was no significant difference between Group I and Group II values for anti-Mic Ab (z = -1.971, P >0.05) and anti-TPO Ab (z = -2.008, P __________________________ >0.05). The relapse rate was independent of antibody positivity (73% vs 48%, x2 = 1.93, P >0.05) for anti-Mic Ab.
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The relapse rate was also independent of anti-TPO Ab positivity (65% vs 52%, x2 = 1.42, P >0.05). There was no significant difference in antibody concentrations between Group I and Group II: z = 1.575, P >0.05 for anti-Mic Ab results, and z = 1.531, P >0.05 for anti-TPO Ab results.
DIscussion
In this study, we measured circulating anti-Mic and anti-TPO Ab in GD patients' sera. The analytical characteristics of the methods used for Ab assay (repeatability and reproducibility, parallel test) appeared quite satisfactory both for anti-Mic and anti-TPO Ab. results (8, 9) . In contrast, a very closecorrelation was observed when comparing the two RIA results (5, 10) .
The present results are fully consistent with such observations, the assays used revealing a strong corre-lation between anti-Mic Ab and anti-TPO Ab in GD patients, either untreated, treated, in remission, or in relapse. Anti-Mic and anti-TPO Ab prevalence in patients before treatment-77%
and 73%, respectivelywas decreased in treated patients-60% anti-Mic and 56% anti-TPO--results that compare well with those reported in the literature: 72-88% anti-Mic Ab-positive (11-13) and 62-87% anti-TPO Ab-positive (7, 11, 14, 15) in untreated GDpatients, which sharply decrease during antithyroid drug treatment (7, 15, 16) .
We also determined in the present study that the relapse rate in GDpatients was correlated to the antiMic and anti-TPO positivity values measured before treatment.
Thus, patients with high Ab concentrations stand little chance of remission under drug treatment. To our knowledge, no study has focused on the utility of anti-TPO Ab assay as a prognostic marker of Graves disease, although the relapse rate has been shown to be high in GDpatients with high serum a#{241}ti-Mic Ab titers The present results on pre-treatment anti-Mic Ab titration are in accord with these studies.
In summary, this study showed that anti-Mic and anti-TPO antibody assays are comparable in analytical reliability and parallelism. Clinically, they produce correlated results in nontreated, treated, remission, and 
